Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05121519 · ClinicalTrials.gov registry record · NA
Does Eliminating Coffee Avoid Fibrillation?
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT05121519 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 200 participants.
The verdict
NCT05121519, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
Given both the increasing population impact of atrial fibrillation (AF) and the widespread consumption of coffee in society, determining an associated benefit or risk of coffee consumption on AF is of great clinical relevance. This study will evaluate the effect of randomly assigning participants undergoing cardioversion to coffee abstinence or coffee continuation over a 6 month period. This study will provide the first, randomized evaluation of coffee on AF outcomes and will provide important information on whether or not coffee has any effect on AF recurrence.
Interventions
- OTHER Consume coffee
- OTHER Avoid coffee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2025-10-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05121519
The ClinicalTrials.gov registry entry for NCT05121519 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Consume coffee is the first listed.
NCT05121519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05121519 about?
NCT05121519 is a clinical study titled "Does Eliminating Coffee Avoid Fibrillation?". Given both the increasing population impact of atrial fibrillation (AF) and the widespread consumption of coffee in society, determining an associated benefit or risk of coffee consumption on AF is of great clinical relevance. This study will evaluate the effect of randomly assigning participants un...
What is the current status of trial NCT05121519?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2021-10-20. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT05121519?
The interventions under investigation include: Consume coffee (OTHER), Avoid coffee (OTHER).
Who is sponsoring clinical trial NCT05121519?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.